Rick Pazdur, a senior FDA official, characterized recent turmoil at the agency as a period of “destruction” that should be used to rethink its structure rather than simply repair it. Speaking at the ASCO 2026 conference, he framed the current moment as a chance to overhaul processes that have long needed change.
The remarks come as the FDA faces increasing pressure from competition with China and internal criticism over its efficiency. Pazdur’s perspective suggests that what some see as a crisis can serve as a catalyst for modernization, particularly in drug review and approval mechanisms.
“We've had a lot of destruction here, and it doesn't mean that we have to just go back and say, well, let's rebuild it as,” Pazdur said, according to STAT News. He did not offer specific numbers or timelines, but his comments point to a fundamental reassessment of agency operations.
The implications for drug developers are significant. A restructured FDA could mean faster or more streamlined reviews, but the path forward remains unclear without concrete proposals. Industry stakeholders will watch closely for any formal restructuring plans.
Critics may argue that the term “destruction” overstates the situation and that any major restructuring risks disrupting patient access to therapies. Without legislative support, Pazdur’s vision may remain aspirational.